Cloud-based system will enable global pricing managers to analyze regulatory trends and simulate the effects of pricing changes
In many nations with single-payer (government) funding of pharmaceutical purchasing, the practice of “reference pricing” has been commonplace. Government negotiators will gather a basket of pricing patterns among other nations, and use some formula to arrive at a desired price point. Meanwhile, individual country managers of multinational pharma companies, dealing with market dynamics within their territories, have tended to make pricing decisions based on local conditions. The result: a decision made in one country can significantly affect pricing in other countries, without the multinational anticipating such effects.
To address this situation, as well as to have more resources to manage an ever-tightening pricing vise, Model N is now offering an international reference pricing module, Model N IRP. Based on surveys of its existing clients (who use Model N for managing analytics of revenue from contracts), global pricing managers are “underequipped” to collaborate across regions, and unable to make fast, data-driven decisions, says Arnaud Grunwald, a senior director at the Redwood Shores, CA, firm. Model N IRP features a user-driven configurator for inputting the rules that would affect a manufacturers’ pricing programs, easy-to-use interfaces, and output to both desktop and mobile devices. The configurator also enables users to perform what-if analyses of pricing decisions. Pharma companies are also on the hook to national agencies to report accurate pricing data, and the program can assist in meeting that requirement.
Model N IRP has already been rolled out to a handful of existing Model N clients; this summer, the program has been updated with user enhancements. In one case, Model N has been able to document a reduction in price erosion by 40% (from 2.5% to 1.5%)—a multimillion-dollar result for the client. Grunwald says that by and large, each client needs to input his or her own international pricing rules, but that the company is discussing the possibility of shared rules information among clients, brought together via the SaaS format of the program.
At the same time, Model N is also offering an enhanced service for scrubbing pricing data coming from pharmacy benefit managers (and others) in the US, as well as where such data are available internationally, in order to manage contracts, chargebacks and other financial transactions more effectively.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.